BioSenic Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	2.1yrs

Recente managementupdates

Recent updates

CEO

BioSenic heeft geen CEO, of we hebben geen gegevens over hen.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Bernard Malissen	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Jean-François Bach	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Yves Sagot	Independent Director	1.8yrs	geen gegevens	geen gegevens
Alain Fischer	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Jean-Luc Vandebroek	Non-Executive Director	2.1yrs	geen gegevens	geen gegevens
Jean-François Rax	Non-Executive Director	2.1yrs	geen gegevens	geen gegevens
Jules Hoffmann	Chairman of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Carlo Chizzolini	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Frédéric Houssiau	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Revital Rattenbach	Independent Director	2.1yrs	geen gegevens	geen gegevens
Jean Stephenne	Independent Director	2.1yrs	geen gegevens	geen gegevens

2.1yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van BT1 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.1 jaar), wat duidt op een nieuw bestuur.

BioSenic Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

BioSenic S.A. Announces Executive Changes

Véronique Pomi-Schneiter Step Down as BioSenic's Deputy CEO

Biosenic S.A. and Its Subsidiary Medsenic SAS Announces the Promotion of Carole Nicco to Chief Operating Officer

BioSenic S.A. Appoints Yves Sagot as Independent Director

BioSenic Appoints Dr. Carole Nicco as Chief Scientific Officer

BioSenic S.A. Appoints Michel Wurm as Interim Chief Medical Officer

Recent updates

BioSenic S.A. Announces Executive Changes

Véronique Pomi-Schneiter Step Down as BioSenic's Deputy CEO

Medsenic, Subsidiary of Biosenic Receives the Intention to Grant Key European Patent from European Patent Office

Biosenic Releases New In-Depth Analysis of Its Positive Phase 2 Clinical Data for Optimal Administration Scheme for Its Next Late-Stage Trial of Arsenic Trioxide (Ato) Targeting Cgvhd

New major risk - Shareholder dilution

BioSenic S.A. to Report Fiscal Year 2023 Results on Jun 06, 2024

Biosenic S.A. Releases Details of Optimized Administration Approach Ahead of Planned Phase 3 Trial of OATO for Chronic Graft-Versus-Host Disease

BioSenic S.A. Patent Granted in Canada for Broader Protection of ATO Therapeutic Platform

BioSenic Presents New Phase 3 Data on JTA-004 to Treat Severe Osteoarthritis Pain at the 2024 OARSI World Congress

BioSenic Files for Additional Patent Protection Following New Clinical Evidence of Efficacy for JTA-004 in OA

Biosenic S.A. and Its Subsidiary Medsenic SAS Announces the Promotion of Carole Nicco to Chief Operating Officer

New major risk - Market cap size

BioSenic S.A. Performs Further Analysis of Its Phase 2 Clinical Trial Data, Leading to an Optimal Administration Scheme for Its Next Late-Stage Trial of Arsenic Trioxide in cGvHD

BioSenic Publishes New Evidence of Beneficial Effects of Arsenic Treatment Supporting Clinical Trial for Systemic Sclerosis

New major risk - Market cap size

BioSenic S.A. Puts Phase IIb Allob Trial on Hold

BioSenic S.A. Appoints Yves Sagot as Independent Director

BioSenic Appoints Dr. Carole Nicco as Chief Scientific Officer

BioSenic S.A. Appoints Michel Wurm as Interim Chief Medical Officer

Less than half of directors are independent

BioSenic SA provides update on its autoimmune disease platform based on ATO (arsenic trioxide)

Less than half of directors are independent

CEO

Bestuursleden

Gemiddelde duur